Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KU-32 is a novel and novobiocin-based Hsp90 inhibitor. It can protect against neuronal cell death.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 624,500 |
50 mg | 約10-14 週間 | ¥ 822,000 |
100 mg | 約10-14 週間 | ¥ 1,124,500 |
説明 | KU-32 is a novel and novobiocin-based Hsp90 inhibitor. It can protect against neuronal cell death. |
In vitro | KU-32 protects against glucose-induced death of embryonic DRG (dorsal root ganglia) neurons cultured for 3 days in vitro. Treating human islets with KU-32 for 24 hours displays no toxicity. KU-32 improves cellular viability by blocking apoptosis, with a minimum of 2-day exposure. When preincubate in KU-32, isolated human islets release more glucose-stimulated insulin [1] [2]. |
In vivo | Administered with KU-32 (10 weeks; diabetic BKS-db/db mice) do not display any obvious changes in blood glucose and insulin levels, despite having greater insulin staining/beta cells in the pancreas compared to untreated BKS db/db mice[1]. |
分子量 | 407.41 |
分子式 | C20H25NO8 |
CAS No. | 956498-70-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
KU-32 956498-70-7 Cytoskeletal Signaling Metabolism HSP KU 32 KU32 Inhibitor inhibitor inhibit